Advanced Soft Tissue Sarcoma with Mark Agulnik, MD Case 1

The FDA granted orphan drug designation for elraglusib, a novel drug for treating advanced soft tissue sarcoma.

In this episode of Targeted Talks, Edwin Choy, MD, PhD, discussed the FDA approval of afamitresgene autoleucel for the treatment of patients with advanced synovial sarcoma.

The study will evaluate silmitasertib, a novel agent, for the treatment of pediatric and adult patients with relapsed/refractory solid tumors.

In season 4, episode 5 of Targeted Talks, Alice P. Chen, MD, discusses important studies that are investigating treatment options for alveolar soft part sarcoma.

In an interview with Targeted Oncology, Sandra P. D'Angelo, MD, discussed the approval and supporting data of afamitresgene autoleucel for the treatment of synovial sarcoma.

Afamitresgene autoleucel is now an FDA-approved treatment for patients with advanced synovial sarcoma.